Karyopharm Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview

Karyopharm Therapeutics

31/10/2023 14:54

* Karyopharm Therapeutics Inc  KPTI.OQ   KPTI.O  is expected
to show a rise in quarterly revenue when it reports  results 
    * The Newton Center Massachusetts-based  company is expected
to
report  a 3.1% increase in revenue to $37.279 million from
$36.15 million a year ago, according to the mean estimate from 9
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Karyopharm
Therapeutics
Inc is for a loss of 28 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Karyopharm
Therapeutics Inc is $6​, above​ its last closing price of $0.82.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.35       -0.34      -0.29     Beat    15.3
 Mar. 31 2023  -0.36       -0.37      -0.30     Beat    18.5
 Dec. 31 2022  -0.35       -0.35      -0.43     Missed  -21.8​
 Sep. 30 2022  -0.58       -0.57      -0.45     Beat    20.4
 ​​Jun.        -0.63       -0.63      -0.62     Beat    2.1
 30 2022                                                
 Mar. 31 2022  -0.62       -0.63      -0.53     Beat    16​
 Dec. 31 2021  -0.35       -0.52      0.46      Beat    189.2
 Sep. 30 2021  -0.69       -0.67      -0.69     Missed  -2.5
 This summary was machine generated October 31 at 14:54 GMT.  All
figures in US dollars  unless otherwise stated